MX2017012423A - Inhibidores de calicreina plasmatica y uso de los mismos para prevenir el ataque del angioedema hereditario. - Google Patents
Inhibidores de calicreina plasmatica y uso de los mismos para prevenir el ataque del angioedema hereditario.Info
- Publication number
- MX2017012423A MX2017012423A MX2017012423A MX2017012423A MX2017012423A MX 2017012423 A MX2017012423 A MX 2017012423A MX 2017012423 A MX2017012423 A MX 2017012423A MX 2017012423 A MX2017012423 A MX 2017012423A MX 2017012423 A MX2017012423 A MX 2017012423A
- Authority
- MX
- Mexico
- Prior art keywords
- hereditary angioedema
- plasma kallikrein
- kallikrein inhibitors
- angioedema attack
- preventing hereditary
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562140277P | 2015-03-30 | 2015-03-30 | |
| US201562140289P | 2015-03-30 | 2015-03-30 | |
| US201562214293P | 2015-09-04 | 2015-09-04 | |
| PCT/US2016/024921 WO2016160926A1 (en) | 2015-03-30 | 2016-03-30 | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017012423A true MX2017012423A (es) | 2018-01-26 |
Family
ID=57005262
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017012423A MX2017012423A (es) | 2015-03-30 | 2016-03-30 | Inhibidores de calicreina plasmatica y uso de los mismos para prevenir el ataque del angioedema hereditario. |
| MX2023010206A MX2023010206A (es) | 2015-03-30 | 2017-09-27 | Inhibidores de calicreina plasmatica y uso de los mismos para prevenir el ataque del angioedema hereditario. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010206A MX2023010206A (es) | 2015-03-30 | 2017-09-27 | Inhibidores de calicreina plasmatica y uso de los mismos para prevenir el ataque del angioedema hereditario. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20180298110A1 (enExample) |
| EP (2) | EP3286226A4 (enExample) |
| JP (3) | JP7008920B2 (enExample) |
| KR (3) | KR102607829B1 (enExample) |
| CN (1) | CN107614532A (enExample) |
| AU (3) | AU2016243160B2 (enExample) |
| BR (1) | BR112017020864A2 (enExample) |
| CA (1) | CA2979713A1 (enExample) |
| CO (1) | CO2017009404A2 (enExample) |
| EA (1) | EA201792161A1 (enExample) |
| HK (1) | HK1250995A1 (enExample) |
| IL (2) | IL305207A (enExample) |
| MX (2) | MX2017012423A (enExample) |
| WO (1) | WO2016160926A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62853B1 (sr) | 2010-01-06 | 2022-02-28 | Takeda Pharmaceuticals Co | Proteini koji vezuju kalikrein plazme |
| AU2012204202A1 (en) | 2011-01-06 | 2013-07-11 | Dyax Corp. | Plasma kallikrein binding proteins |
| CA3208188A1 (en) | 2013-03-15 | 2014-09-25 | Takeda Pharmaceutical Company Limited | Anti-plasma kallikrein antibodies |
| PT3096798T (pt) | 2014-01-21 | 2021-02-25 | Dyax Corp | Proteínas de ligação à calicreína plasmática e seus usos no tratamento de angioedema hereditário |
| AU2015235967B2 (en) | 2014-03-27 | 2020-10-22 | Takeda Pharmaceutical Company Limited | Compositions and methods for treatment of diabetic macular edema |
| CN116077648A (zh) * | 2015-12-11 | 2023-05-09 | 武田药品工业株式会社 | 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途 |
| IL314752A (en) * | 2016-09-16 | 2024-10-01 | Takeda Pharmaceuticals Co | Metabolite biomarkers for diseases associated with the contact activation system |
| AU2018311976B2 (en) * | 2017-08-04 | 2022-10-13 | Takeda Pharmaceutical Company Limited | Inhibitors of Plasma Kallikrein and uses thereof |
| WO2019166572A1 (en) * | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor |
| JP2021515761A (ja) * | 2018-02-28 | 2021-06-24 | ライフサイ ファーマシューティカルズ，インク． | 遺伝性血管浮腫の治療 |
| AU2019328324B2 (en) * | 2018-08-30 | 2025-06-19 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| MX2022008649A (es) | 2020-01-13 | 2022-09-23 | Takeda Pharmaceuticals Co | Inhibidores de calicreina plasmatica y sus usos para tratar episodios de angioedema hereditario pediatrico. |
| CN115697403A (zh) * | 2020-03-10 | 2023-02-03 | 迪赞纳生命科学公开有限公司 | Il-6/il-6r抗体的组合物及其使用方法 |
| CN114166924B (zh) * | 2021-12-03 | 2024-11-22 | 中国医学科学院北京协和医院 | 尿液蛋白标志物在诊断遗传性血管水肿中的用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| PT739355E (pt) | 1994-01-11 | 2005-01-31 | Dyax Corp | Proteinas de 'dominio de kunitz' inibidoras de calicreina e seus analogos |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| CA2488558C (en) | 2002-06-07 | 2013-08-20 | Dyax Corp. | Prevention and reduction of blood loss |
| US7132100B2 (en) * | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| RS62853B1 (sr) * | 2010-01-06 | 2022-02-28 | Takeda Pharmaceuticals Co | Proteini koji vezuju kalikrein plazme |
| AU2012204202A1 (en) * | 2011-01-06 | 2013-07-11 | Dyax Corp. | Plasma kallikrein binding proteins |
| US10040855B2 (en) * | 2011-05-02 | 2018-08-07 | Millennium Pharmaceuticals, Inc. | Formulation for anti-α4β7 antibody |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| IL273688B2 (en) * | 2013-01-20 | 2024-12-01 | Dyax Corp | Evaluation and treatment of bradykinin-mediated disorders |
| CA3208188A1 (en) * | 2013-03-15 | 2014-09-25 | Takeda Pharmaceutical Company Limited | Anti-plasma kallikrein antibodies |
| KR20140119396A (ko) * | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
| EP3060582B1 (en) * | 2013-10-21 | 2020-09-23 | Dyax Corp. | Assays for determining plasma kallikrein system biomarkers |
| PT3096798T (pt) * | 2014-01-21 | 2021-02-25 | Dyax Corp | Proteínas de ligação à calicreína plasmática e seus usos no tratamento de angioedema hereditário |
-
2016
- 2016-03-30 IL IL305207A patent/IL305207A/en unknown
- 2016-03-30 MX MX2017012423A patent/MX2017012423A/es unknown
- 2016-03-30 WO PCT/US2016/024921 patent/WO2016160926A1/en not_active Ceased
- 2016-03-30 KR KR1020177031279A patent/KR102607829B1/ko active Active
- 2016-03-30 EP EP16774069.5A patent/EP3286226A4/en not_active Withdrawn
- 2016-03-30 JP JP2017549388A patent/JP7008920B2/ja active Active
- 2016-03-30 CN CN201680018200.7A patent/CN107614532A/zh active Pending
- 2016-03-30 CA CA2979713A patent/CA2979713A1/en active Pending
- 2016-03-30 IL IL254292A patent/IL254292B2/en unknown
- 2016-03-30 EP EP21167802.4A patent/EP3916020A1/en active Pending
- 2016-03-30 US US15/562,671 patent/US20180298110A1/en not_active Abandoned
- 2016-03-30 BR BR112017020864-4A patent/BR112017020864A2/en not_active Application Discontinuation
- 2016-03-30 KR KR1020257012913A patent/KR20250057946A/ko active Pending
- 2016-03-30 HK HK18110329.1A patent/HK1250995A1/zh unknown
- 2016-03-30 AU AU2016243160A patent/AU2016243160B2/en active Active
- 2016-03-30 EA EA201792161A patent/EA201792161A1/ru unknown
- 2016-03-30 KR KR1020237040648A patent/KR102799778B1/ko active Active
-
2017
- 2017-09-15 CO CONC2017/0009404A patent/CO2017009404A2/es unknown
- 2017-09-27 MX MX2023010206A patent/MX2023010206A/es unknown
-
2021
- 2021-10-13 US US17/500,214 patent/US20220169749A1/en active Pending
- 2021-12-16 JP JP2021204200A patent/JP7309836B2/ja active Active
-
2022
- 2022-05-12 AU AU2022203180A patent/AU2022203180B2/en active Active
-
2023
- 2023-07-05 JP JP2023110592A patent/JP7826251B2/ja active Active
-
2025
- 2025-11-21 AU AU2025271115A patent/AU2025271115A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017012423A (es) | Inhibidores de calicreina plasmatica y uso de los mismos para prevenir el ataque del angioedema hereditario. | |
| MX2021013665A (es) | Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario. | |
| EP4193993A3 (en) | Combinations of cannabinoids and n-acylethanolamines | |
| IL259691A (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
| MX2021012155A (es) | Composiciones y metodos para el tratamiento de la anemia. | |
| MX2019004500A (es) | Terapia de combinación para la inhibición de componente de complemeto (c3). | |
| TN2015000349A1 (en) | CDC7 Inhibitors | |
| CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| MX2016003843A (es) | Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
| EA201790170A1 (ru) | Терапевтические соединения-ингибиторы | |
| TR201819092T4 (tr) | Serin proteaz inhibitörleri olarak multi-sübstüte edilmiş aromatik bileşikler. | |
| BR112015011756A2 (pt) | inibidores da glutamase e métodos de uso | |
| EA201891132A1 (ru) | Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента | |
| BR112015023207A2 (pt) | uso de c1-inh no tratamento de desordens associadas à deficiência de inibidor de c1 esterase | |
| CL2015003595A1 (es) | Inhibidores/antiandrógenos novedosos de cyp17 | |
| CL2015002897A1 (es) | Inhibidores de bace1 | |
| EP4616910A3 (en) | Pcna inhibitors | |
| MX2019005833A (es) | Administracion transdermica de agentes grandes. | |
| PH12017501022A1 (en) | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same | |
| EP4480577A3 (en) | Structured elements and methods of use | |
| MX373177B (es) | Métodos de tratamiento de disquinesia y trastornos relacionados. | |
| WO2014113492A3 (en) | Anti-viral compounds | |
| IL251881A0 (en) | Preparations for the treatment of acute, post-operative or chronic pain and methods of using them | |
| NZ713440A (en) | Nsaid administration and related compositions, methods and systems. |